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Background: A single-chain bispecific antibody (scBsAb; an engineered antibody),
has promising clinical applications. Nonetheless, the effect of different interchain
linkers on its activity is poorly understood.
Methods: Gene synthesis was used to splice the anti-γ-seminoprotein single-chain
antibody (anti-γ-Sm scFv) gene with the anti-CD3 single-chain antibody (anti-CD3
scFv) gene via different interchain peptide linkers. The Phyre2 software was used to
predict spatial configuration of different scBsAbs. Eukaryotic expression vectors carrying
scBsAbs were constructed by molecular cloning techniques and these plasmids were
transfected into HeLa cells with liposomes. scBsAbs were purified by Ni2+-NTA agarose
and analysed for antigen binding by an enzyme-linked immunosorbent assay (ELISA).
Blood pharmacokinetics and inhibition of prostate tumour growth in nude mice were
analysed in in vivo experiments.
Results: Bioinformatics analysis and prediction showed that none of the three linkers,
Fc, 205C’, and HSA, had a significant effect on protein folding of anti-γ-Sm scFv or
anti-CD3 scFv. Nevertheless, the spatial structures of the three linkers were noticeably
different. Anti-γ-Sm × anti-CD3 scBsAb with an Fc, 205C’, or HSA linker was successfully
constructed, and these antibodies had similar protein expression levels. ELISA showed
that all the three scBsAbs bound to Jurkat cells and the LNCaP membrane antigen,
although binding of (205C’)scBsAb was weaker than that of the two parental
scFvs (P < 0.05). In contrast, binding strength of (HSA)scBsAb and (Fc)scBsAb was
close to that of the parental scFvs (P > 0.05). Pharmacokinetic analysis showed
that the half-clearance time of the elimination phase (T1/2β) for (HSA)scBsAb was
the longest: up to 4.4 h. Compared with γ-Sm ScFv, the three scBsAbs all had a
much stronger inhibitory effect on the growth of prostate cancer (P < 0.05), but
there were no significant differences among the three scBsAbs (P > 0.05).
Conclusions: HSA is the optimal linker for the anti-γ-Sm × anti-CD3 scBsAb and
may improve antigen-binding affinity of antibodies and prolong physiological
retention time. Interchain linkers affect the function of scBsAbs; these effects
may have important implications for construction of antibodies.
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Prostate cancer, with such features as a long incubation period and high incidence,
ranks the second among male malignant tumours in terms of incidence [1]. The con-
ventional treatments for prostate cancer include surgery, corticosteroids, radiotherapy
or chemotherapy. With the deepening of anti-tumor immune mechanism research and
the discovery of a variety of tumor-associated surface antigen, the clinical trials for
prostate cancer immunotherapy have been widely carried out. Currently, cytokines are
the most involved in prostate cancer immunotherapy such as interleukin-2 (IL-2) and
granulocyte macrophage colony-stimulating factor (GM-CSF) [2]. Cytokines can be applied
as immunoadjuvants, recombinant proteins independently or combines with different
tumor-associated antigens (TAA) to prompt the specific anti-tumor immune response. Be-
sides, pre-clinical trials have demonstrated that the vaccine based on prostate specific anti-
gen (PSA) can stimulate humoral and cellular immunity [3]. γ-Seminoprotein(γ-Sm) is the
specific antigen secreted by a prostate tumour and is located in prostate cancer cells and
their metastases. It is the specific biomarker of prostate cancer and is used for diagnosis and
treatment of this disease [4, 5].
Targeting of a tumour-related antigen is the starting point of tumour immunother-
apy. Researchers try multiple methods to modify antibody molecules to enhance their
function [6, 7]. It is now a hot topic in this field of research to link a single-chain anti-
body with other effector molecules to construct fusion proteins with anti-tumour prop-
erties. Accordingly, a bispecific antibody (BsAb) is one of directions in this field aimed
at improvement of tumour immunotherapy via engineering of antibodies [8]. A BsAb
contains two kinds of specific antigen binding sites that can build a bridge between
tumour cells and immune effector cells and thereby to trigger a cytotoxic reaction and
launch targeted killing of the tumour cells [9]. Mashall et al. [10] designed and con-
structed a fusion protein of anti-ErbB2 scFv and CD28; this fusion protein could be
used for targeting of breast cancer cells positive for ErbB2 expression, providing a
stimulatory signal for activation of T cells Report of Vaishampayan et al. [11] provided
a strong rationale for developing phase II trials to determine whether ATC armed with
Her2Bi (aATC) are effective for treating castrate resistant prostate cancer.
A single-chain bispecific antibody (scBsAb) is expressed as a single-chain bispecific
molecule because researchers linked the genes of different single-chain antibody frag-
ments through a peptide linker at the genetic level [12]. Due to the covalent bond be-
tween different antibody fragments, a scBsAb is rather stable and easy to overexpress
in various expression vector systems. Currently, there are several amino acid sequences
available as linkers for construction of scBsAbs. Mallender et al. [13] designed the
linker CBH124 amino acid residues long. Gruber et al. [14] used 205C’ (25 amino acid
residues) to construct an anti-T-cell receptor × anti-fluorescence scBsAb. Such inter-
chain linkers may help each component of a scBsAb to fold correctly and preserve the
binding affinity for the corresponding antigens.
Extensive research into the effects of interchain linkers on biological activity of
scBsAbs may facilitate identification of an optimal linker and construction of a scBsAb.
In the present study, we designed and constructedanti-γ-Sm × anti-CD3 scBsAbs with
different interchain linkers. We examined the effects of different linkers on antibody
expression, antigen binding, and metabolic characteristics in vivo as well as the inhibi-
tory action on prostate cancer.
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Analysis of three-dimensional conformation of scBsAbs
Results of prediction by the Phyre2 online software (Fig. 1) showed that scBsAbs con-
nected by Fc, 205C’, or HSA could fold correctly to form complete proteins, and the re-
spective three-dimensional structures of anti-γ-Sm scFv and anti-CD3scFv were not
seriously affected. Nevertheless, there were differences in the structures of the separated
Fc, 205C’, and HSA peptide fragments. Fc consists of two β-sheets and one α-helix; 205C’
is composed of random coils; and HSA contains two α-helices. The differences in struc-
ture among the three linkers may underlie the differences in biological activities of the
three resulting scBsAbs.Construction and expression of scBsAbs
When an expression vector was digested by HindIII and EcoRI, the bands of γ-Sm scFv
and anti-CD3 scFv could be seen as bands of 741 bp and 729 bp, respectively. The length
of (Fc)scBsAb, (205C’)scBsAb, and (HSA)scBsAb was ~1.6 kb (Fig. 2a). SDS-PAGE ana-
lysis of the purified proteins showed that γ-Sm scFv and anti-CD3 scFv were ~26kD,
whereas (Fc)scBsAb, (205C’)scBsAb, and (HSA)scBsAb were ~57kD (Fig. 2b). These re-
sults were consistent with the software predictions, indicating that the desired genes were
inserted successfully into the expression vector pSectag2B and the corresponding proteins
were successfully expressed and purified.Antigen binding activity assay
Measurement of the antigen binding activity (Fig. 3) showed that the antigen binding of
each scBsAb was much stronger than that of a negative control (skim milk; P < 0.01); this
result indicated that the three kinds of scBsAb bind to Jurkat cells and to the LNCaP
membrane antigen. The antigen binding activity of (205C’)scBsAb was weaker than thatFig. 1 Prediction of tertiary structure model. a, b, c: Tertiary structure respectively for (Fc)scBsAb, (205C’)
scBsAb and (HSA) scBsAb; (d, e, f): Tertiary structure respectively for intrachain linkers Fc, 205C’ and HSA
Fig. 2 Detection of eukaryotic expression of scBsAbs. a. Restriction enzyme cleave identification of
pSectag2B-scBsAbs plasmids; b. SDS-PAGE analysis of purified scBsAbs
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ing similar to that of parental scFvs (P > 0.05).
Pharmacokinetic analysis
A two-compartment model was used for blood clearance curve fitting. The blood
pharmacokinetics-fitting equation of each antibody was derived and half-clearanceFig. 3 Antigen binding activity of scBsAbs measured by ELISA. Note: vs Skim milk, **p < 0.01; vs γ-Sm
ScFv, #p < 0.05
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sults (Table 1) showed that the T1/2αvaluesof the three scBsAbs were very similar
(and small), indicating that they would spread rapidly within the mouse body. Never-
theless, the differences in T1/2βwere quite obvious: T1/2β of (HSA)scBsAb was the
longest, up to 4.4 h.
Therapeutic effects of the scBsAbs
Five healthy nude mice that received an intravenous injection of each antibody and ef-
fector cells showed no obvious pathological changes, indicating that each antibody and
each type of effector cells had no obvious adverse effects. Among the 50 nude mice that
we used as a prostate cancer model, two died (one died of infection, and the other had an
unclear cause of death). The remaining 48 mice were used in the treatment experiment
and were subdivided into five groups: the (Fc)scBsAb group (ten mice), (205C’)scBsAb
group (ten mice), (HSA)scBsAb group (ten mice), γ-Sm ScFv group (ten mice), and the
Control group (eight mice). The results showed that in comparison with the control
group, the growth of the prostate tumour in the treatment group was significantly inhib-
ited (P < 0.05).In comparison with the γ-Sm ScFv group, the inhibitory effect on tumour
growth in groups(Fc)scBsAb, (205C’)scBsAb, and (HSA)scBsAb was much stronger
(P < 0.05). There were no significant differences among groups (Fc)scBsAb, (205C’)scBsAb,
and (HSA)scBsAb (P > 0.05; Fig. 4).
Discussion
Selection of a peptide linker during the design of a scBsAb is an important step. Some
studies [15, 16] suggested that the linker should be long and flexible enough to ensure
that the two half-molecules connected could have sufficient spatial freedom to perform
their functions; on the other hand, the effect on stability of the fusion protein should
also be considered. Besides, the size and affinity of an antibody can affect the blood
pharmacokinetics. The increase of an antibody’s molecular weight mayslow down its
elimination within the body but will weaken tumour penetration [17].
Gustavsson [18] suggested that the length range of linkers for construction of
scBsAbs should be 4–44 amino acid residues. Too short a linker may cause spatial
steric hindrance within the recombinant molecule, affecting the folding of the protein
domains. On the other hand, if the linker is too long, it may enhance undesirable im-
munogenicity of the antibody. The scFv intrachain linker that we utilised in the present
study is a common one: (Gly4Ser)3. Interchain linker Fc is a fragment of human
IgG1CH2 (amino acid positions 297–322), 26 amino acids long. HSA is 25 amino acids
long and contains no cysteine but many polar amino acids (it comes from the human
serum albumin domain D3).205C’ is a 25-amino-acidpeptidefrom a study by Gruber
et al. [14]. We analysed the scBsAbs (that were constructed with different peptideTable 1 Pharmacokinetic parameters of scBsAb with different interchain linker
scBsAb Fitted equation T1/2α T1/2β Goodness of fit
(min) (min) (R2)
125I -(Fc) scBsAb y = 8.67e−0.0041t + 4.75e−0.005t 16.1 168.7 0.998
125I -(205C’) scBsAb y = 1.86e−0.0038t + 4.75e−0.0061t 17.4 119.5 0.995
125I -(HSA) scBsAb y = 14.12e−0.0432t + 2.89e−0.0035t 17.2 264.2 0.999
Fig. 4 Therapeutic effect analysis of scBsAbs
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showed that the spatial conformations of the three scBsAbs exactly matched the native
conformations of the parental antibodies. The prediction and simulation results may
not necessarily reflect the real-life data [19]. Nevertheless, our recombinant BsAbs had
a big molecular weight. Close attention should be paid to the type of expression system:
prokaryotic or eukaryotic. Prediction of the three-dimensional structure of a protein
can form the theoretical foundation for successful expression [20]. Accordingly, we
measured the expression and binding activity of the scBsAbs. In addition, the scBsAbs
were linked to a His and Myc tag, making the purification and identification of the fu-
sion proteins more convenient. Our results indicated that the three scBsAbs all had a
specific binding affinity for Jurkat cells and the LNCaP membrane antigen although the
antigen binding activity of (205C’)scBsAb was weaker than that of parental scFvs and
the other two scBsAbs. As for pharmacokinetics, the half-clearance time of the elimin-
ation phase (T1/2β) of (HSA)scBsAb was the longest. Such differences may be due to
the differences in the structures of the three interchain linkers.
In fact, multiple factors such as the length of the linker, amino acid composition, gly-
cosylation status, and the suitability of each half-molecule when attached to the linker
all affect the function and stability of the fusion protein [21–23]. Kikuchi et al. [24]
constructed an anti-CD47 bivalent single-chain MABL sc(Fv)2 with the linker
(Gly4Ser)3 of 15 amino acids and showed that the recombinant antibody and parental
antibody had almost the same affinity for the antigen and good anti-tumour activity.
Goel et al. [25] constructed a bivalent single-chain antibody with good immunological
competence with a linker composed of 25 amino acids but didn’t obtain exactly the
immunological competence of the parental antibody. According to our results, HSA is
the optimal interchain linker and can prolong half-life of the antibody significantly and
may substantially improve therapeutic effectiveness of minimolecular antibodies. In a
word, the bispecific antibodies make a bridge between the tumor cell and the immune
effector cell, which will trigger the cytotoxic responses. The linker is critical for the
structure of the whole single-chain bispecific antibody molecule. Application of appro-
priate linker can supply enough flexibility for the two binding sites of modified anti-
body to promote the crosslinking between antibody with double antigen sites [26].
The length and composition of linker used to connect the bivalent single-chain anti-
body often affect the stability and function of the newly formed antibody. The most
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and protease resistance [27]. In addition, the middle linker mainly determines the distance
between the two antigen-binding sites of the same specificity. Too short distances may
preclude bivalent binding of the BsAb to the cell surface, although the probability of
the antibody binding to the cell surface bivalently also depends on the antigen density
and accessibility. The linker also influences the flexibility of the molecule, the possibility
of acquiring the most suitable conformation for binding to the antigen [28].Conclusions
According to our study, HSA is the optimal linker for ananti-γ-Sm × anti-CD3 scBsAb;
this linker improves the antigen binding activity of such antibodies and prolongs the re-
tention time in comparison with the other linkers: Fc and 205C’. Composition of the
interchain linker may affect the function of the scBsAb; therefore, rational selection
and design of the linker are crucial for construction of an ideal engineered antibody.Materials and methods
Materials
The pUC18 and pSectag2B plasmids, restriction endonucleases, and DNA ligase were
all purchased from TaKaRa Bio Inc. (Tokyo, Japan); plasmids pUC18-γ-Sm ScFv and
pUC18-CD3 ScFv were constructed and stored in our laboratory. JM109 competent
cells and HeLa cells were purchased from Tiangen Biotech Co., Ltd. (Beijing, China).
The Lipofectamine2000 transfection kit was from Invitrogen Corporation (CA, USA).
The ELISA kit was purchased from Shanghai Ding Biological Technology Co., Ltd.
(Shanghai, China). Balb/c mice and nude mice were provided by the Animal Experi-
mental Center of Zhengzhou University.Design and synthesis of scBsAbs
The scBsAbs was designed on the basis of nucleotide sequences of anti-γ-Sm scvF [29]
and anti-CD3 scFv [30]. The intrachain peptide linkers of scFv consisted of the com-
mon linker: (Gly4Ser)3. The interchain peptide linker between the two kinds of scFvs
was Fc, 205C’, or HSA. Restriction site HindIII and site EcoRI were introduced at one
of the ends of the complete DNA sequence of the scBsAb. The designed gene se-
quences were synthesised by Shanghai Sangon Biotech Co., Ltd.Prediction of spatial conformation
The Phyre 2 online software was used to construct three-dimensional models of
(Fc)scBsAb, (205C’)scBsAb, and (HSA)scBsAb. We analysed interchain linker sequences
when combined with ten amino acid residues close to the opposite ends of the se-
quence. Differences in spatial conformation of scBsAbs were compared.Construction of a eukaryotic expression vector
The synthesised scBsAb gene fragments were cloned into the pUC18 plasmid for
screening of successful positive clones. By sequencing, we found that the scBsAb gene
fragments had been inserted into the pUC18 vector successfully, and the recombinant
sequences pUC18-(Fc)scBsAb, pUC18-(205C’)scBsAb, and pUC18-(HSA)scBsAb were
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HSA)scBsAb, pUC18-γ-Sm ScFv, and pUC18-CD3 ScFv. The purified scBsAb(Fc/205C’/
HSA) and scFv gene fragments were linked by means of T4 ligase with pSectag2B (secretory
eukaryotic expression vector with a 6 ×His and Myc tag at downstream polyclonal loci)
digested by HindIII and EcoRI, which were introduced into JM109 competent cells. A posi-
tive clone was identified after screening and named pSectag2B-(Fc)scBsAb, pSectag2B-
(205C’)scBsAb, pSectag2B-(HSA) scBsAb, pSectag2B-γ-Sm ScFv, or pSectag2B-CD3 ScFv.
Then the plasmids were isolated and prepared in sufficient quantities.Cultivation of HeLa cells and plasmid transfection
Cryovials of HeLa cells were taken out of storage quickly and thawed in a shaking bath at
37 °C. Under aseptic conditions, a suspension of HeLa cells was transferred to a centrifuge
tube. A 10-fold volume of the RPMI1640 culture medium was added, and the mixture was
centrifugated at 350 g for 10 min. The cells were resuspended in the complete medium gen-
tly and then seeded in a 25-cm2 culture flask. After cultivation at 37 °C and 5 %CO2 with
saturated humidity for 24 h, the medium was refreshed for further cultivation. When the
HeLa cells attained 80 % confluence, they were subcultured1:3. On the day before transfec-
tion, the cells were harvested by trypsinisation. The cell concentration was adjusted, and the
cells were seeded in a 12-well plate containing the culture medium without antibiotics at
the density 2.5 × 105 cells/well. We diluted 1.5 μL of Lipofectamine2000 to 20 μL with
DMEM and then mixed it with 20 μL of a pSectag2B-scBsAb or pSectag2B-ScFv solution
(1 μg/μL); the mixture was incubated for 5 min and then transfected into HeLa cells. Mean-
while, the pSectag2B plasmid without the antibody gene was transfected into a separate
batch of HeLa cells, which served as a control. The medium was changed after 5-h transfec-
tion. After cultivation of the cells for 72 h in a CO2 incubator at 37 °C, the culture medium
was collected for isolation of the antibodies. The proteins were purified by Ni2+-NTA agar-
ose, and 25-μL aliquots were used for SDS-PAGE analysis.Measurement of antigen binding activity of the scBsAbs by ELISA
Jurkat cells or the LNCaP membrane antigen at 50 μg/mL were used to coat an ELISA
plate (incubation at 4 °C overnight). 1 % solution of BSA was used to block nonspecific
antigens at 37 °C for 2 h, and then 100 μL of a solution of various antibodies (20 μg/mL)
was added, with subsequent incubation at 37 °C for 2 h. After washes with TPBS and PBS
(three times each), 100 μL of a mouse anti-human Myc antibody (1:2,000) was added, and
the mixture was incubated at 37 °C for 1 h. After three washes each with TPBS and PBS,
100 μL of a horseradish peroxidase-conjugated goat anti-mouse IgG antibody (1:5,000)
was added and incubated at 37 °C for 1 h, followed by three washes each with TPBS and
PBS. Finally, 100 μL of the tetramethylbenzidine (TMB) substrate (1 mg/mL TMB,
0.1 mM sodium acetate pH6.0, and 0.006 %H2O2) was used for visualisation (incubation
for 20 min). We added 50 μL of 1Msulphuric acid to each well to terminate the reaction.
Absorbance at 450 nm was measured, with reference wavelength 630 nm.An assay of blood pharmacokinetics
The iodogen method was used for radioiodination of the antibodies. Thirty Balb/c mice
were randomly distributed into three groups. The mice in each group received an
Hao et al. Theoretical Biology and Medical Modelling  (2015) 12:14 Page 9 of 10injection of 0.5 mL of125I-scBsAb through the caudal vein. Then, 10 μL of blood was
collected from the tail vein at the time points0, 5 min, 15 min, 30 min, and 24 h after
the injection. After that, radioactivity counts were recorded, and blood clearance pa-
rameters were calculated.Preparation of effector cells and treatment with scBsAbs
Density gradient centrifugation was used to isolate peripheral blood mononuclear cells
(PBMCs) from normal blood after heparinisation. PBMCs were precooled and resus-
pended in PBS, then centrifuged at 350 g for 10 min. With the supernatant discarded,
the RPMI1640 culture medium containing 10 % foetal calf serum, 2 mM glutamine,
100U/mL penicillin, and 100 μg/mL streptomycin was added to resuspend the cells,
and the cell suspension was then transferred to 250-mL cell culture flasks, placed in an in-
cubator with 5 % CO2 at 37 °C for 1-h incubation. Non-adherent cells were transferred
into a new culture flask, with the culture medium changed and 150U/mL IL-2 added.
After incubation at 37 °C for 3d, the culture medium was changed again and the concen-
tration of IL-2 was adjusted to 105U/mL. Later, the culture medium was changed every
three days, and the effector cells were obtained after constant cultivation for eight weeks.
First, five healthy nude mice received an injection (200 μg) of one of the antibodies
(each mouse per antibody) and 107 effector cells, for analysis of adverse effects of each
kind of antibody and effector cells. Fifty nude mice were subdivided into five groups
randomly (10 per group): the (Fc)scBsAb group, (205C’)scBsAb group, (HSA)scBsAb
group, γ-Sm ScFv group, and the Control group. Nude mice in each group received
ventral subcutaneous injection of 107 LNCaP cells. When gross tumour volume was
~100 mm3, the treatment plan for each group started along with monitoring. Mice in
the Control group received only the intravenous injection of 107effector cells, and those
in the treatment group received an intravenous injection of 107effector cells and 200 μg
of one of the antibodies. The volume of the tumour was measured once a week. The
formula for calculation of the tumour volume was length × width2 × 0.52. After six
weeks, the nude mice were killed by CO2 asphyxiation.
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